Type 2 quasars are luminous active galactic nuclei whose central regions are obscured by large amounts of gas and dust. In this paper, we present a catalog of type 2 quasars from the Sloan Digital Sky Survey, selected based on their optical emission lines. The catalog contains 887 objects with redshifts z < 0.83; this is 6 times larger than the previous version and is by far the largest sample of type 2 quasars in the literature. We derive the [O iii]5007 luminosity function (LF) for 10 8.3 L < L [O iii] < 10 10 L (corresponding to intrinsic luminosities up to M[2500 Å] −28 mag or bolometric luminosities up to 4 × 10 47 erg s −1 ). This LF provides robust lower limits to the actual space density of obscured quasars due to our selection criteria, the details of the spectroscopic target selection, and other effects. We derive the equivalent LF for the complete sample of type 1 (unobscured) quasars and determine the ratio of type 2 to type 1 quasar number densities. Our data constrain this ratio to be at least ∼ 1.5:1 for 10 8.3 L < L [O iii] < 10 9.5 L at z < 0.3, and at least ∼ 1.2:1 for L [O iii] ∼ 10 10 L at 0.3 < z < 0.83. Type 2 quasars are at least as abundant as type 1 quasars in the relatively nearby universe (z 0.8) for the highest luminosities.
IMPORTANCE Cardiovascular disease (CVD) is the leading cause of death in the United States. OBJECTIVE To review the evidence on screening asymptomatic adults for CVD risk using electrocardiography (ECG) to inform the US Preventive Services Task Force.
Large-scale shotgun sequencing (RNA-seq) analysis of mRNAs in dormant Bacillus subtilis spores prepared on plates or in liquid generally found the same ∼46 abundant mRNA species, with >250 mRNAs detected at much lower abundances. Knowledge of the amount of phosphate in a single B. subtilis spore allowed calculation of the amount of mRNA in an individual spore as ∼106 nucleotides (nt). Given the levels of abundant spore mRNAs compared to those of other mRNAs, it was calculated that the great majority of low-abundance mRNAs are present in only small fractions of spores in populations. Almost all of the most abundant spore mRNAs are encoded by genes expressed late in sporulation in the developing spore under the control of the forespore-specific RNA polymerase sigma factor, σG, and most of the encoded proteins are in spores. Levels of the most abundant spore mRNAs were also relatively stable for a week at 4°C after spore harvest. RNA-seq analysis of mRNAs in highly purified and less-well-purified spores made in liquid, as well as from spores that were chemically decoated to remove possible contaminating mRNA, indicated that low-abundance mRNAs in spores were not contaminants in purified spore preparations, and several sources of low-abundance mRNAs in spores are suggested. The function of at least the great majority of spore mRNAs seems most likely to be the generation of ribonucleotides for new RNA synthesis by their degradation early in spore revival.
IMPORTANCE Previous work indicates that dormant Bacillus subtilis spores have many hundreds of mRNAs, some of which are suggested to play roles in spores’ “return to life” or revival. The present work finds only ∼46 mRNAs at ≥1 molecule spore, with others in only fractions of spores in populations, often very small fractions. Less-abundant spore mRNAs are not contaminants in spore preparations, but how spores accumulate them is not clear. Almost all abundant spore mRNAs are synthesized in the developing spore late in its development, most encode proteins in spores, and abundant mRNAs in spores are relatively stable at 4°C. These findings will have a major impact on thinking about the roles that spore mRNAs may play in spore revival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.